Accendra Health financials
$0.6120−5.85%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 |
|---|---|---|
| Revenue | $613.2M | $627.8M |
| Gross profit | $263.4M | $278.0M |
| Gross margin | 43.0% | 44.3% |
| Operating income | -$35.1M | $17.1M |
| Net income | -$89.1M | -$6.5M |
| Net margin | −14.5% | −1.0% |
| Diluted EPS | $-1.16 | $-0.08 |
| EBITDA | $59.8M | $78.9M |
| Operating cash flow | -$26.0M | -$50.1M |
| Free cash flow | -$73.6M | -$91.7M |
| Diluted shares | 76.7M | 76.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 |
|---|---|---|
| Cash & equivalents | $7.7M | $336.9M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $1.72B | $2.10B |
| Total assets | $2.11B | $2.42B |
| Total liabilities | $2.66B | $2.88B |
| Shareholders' equity | -$550.9M | -$464.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology